Overall survival and progression free survival for trials comparing surgery (± other treatment) with non-surgical treatment
| Study | Arm 1 | Arm 2 | RR (95% CI) |
|---|---|---|---|
| OS, overall survival; PFS, progression free survival; RTOG, Radiation Therapy Oncology Group; RR, relative risk; CI, confidence interval. | |||
| MRC, UK25 | Surgery | Radiotherapy | |
| 4 year OS 23% | 4 year OS 7% | 3.27 (0.74 to 14.42), p = 0.12 | |
| Squamous cell subgroup analysis 30% | Squamous cell subgroup analysis 6% | 5.10 (0.68 to 38.29), p = 0.11 | |
| NCI, USA27 | Initially inoperable, radiotherapy | Initially inoperable, radiotherapy | |
| Surgery | No surgery | ||
| 5 year OS 8% | 5 year OS 6% | 1.42 (0.42 to 4.81), p = 0.57 | |
| 5 year PFS 6% | 5 year PFS 4% | 1.58 (0.39 to 6.38), p = 0.52 | |
| National Cancer Institute of Canada, North America26 | Chemotherapy then surgery | Radiotherapy | |
| 2 year OS 44% | 2 year OS 40% | 1.09 (0.48 to 2.51) | |
| Intergroup 0139 trial(RTOG 93–09), North America20 | Concurrent chemotherapy and radiotherapy then surgery | Concurrent chemotherapy and radiotherapy | 1.53 |
| Treatment deaths 14 | Treatment deaths 3 | 4.43 (1.29 to 15.19), p = 0.02 | |
| 3 year PFS 29% | 3 year PFS 19% | (1.06 to 2.21), p = 0.02 | |
| 3 year OS 38% | 3 year OS 33% | 1.16 (0.89 to 1.52), p = 0.27 | |